Literature DB >> 8318419

Oral versus intravenous administration of 5-aminolaevulinic acid for photodynamic therapy.

C S Loh1, A J MacRobert, J Bedwell, J Regula, N Krasner, S G Bown.   

Abstract

Endogenously synthesised protoporphyrin IX (PpIX) following the administration of 5-amino-laevulinic acid (ALA) is an effective photosensitiser for photodynamic therapy (PDT). Following intravenous administration, PpIX accumulates predominantly in mucosa of hollow viscera and on light exposure, mucosal ablation results with relative sparing of the submucosa and muscularis layers. Oral administration is effective with ALA in contrast to conventional exogenous photosensitisers such as haematoporphyrin derivative and phthalocyanines. Oral administration of ALA is also simpler, safer, cheaper and more acceptable to patients. We studied the porphyrin sensitisation kinetics profile in the stomach, colon and bladder in normal rats following enterally and parenterally administered ALA using microscopic fluorescence photometric studies of frozen tissue sections. Mucosal cells in all three organs exhibit higher fluorescence levels as compared with underlying smooth muscle following both intravenous and oral administration. Peak concentration were seen 4 h after sensitisation at the highest doses used (200 mg kg-1 i.v., 400 mg kg-1 oral), and slightly earlier with lower doses. The temporal kinetics of both routes of administration were similar although a higher oral dose was required to achieve the same tissue concentration of PpIX. The highest level of fluorescence was achieved in the gastric mucosa and in decreasing levels, colonic and bladder mucosa. A similar degree of mucosal selectivity was achieved in each organ with each route of administration but an oral dose in excess of 40 mg kg-1 was required to achieve measurable PpIX sensitisation. In a pilot clinical study, two patients with inoperable rectal adenocarcinomas were given 30 mg kg-1 and one patient with sigmoid colon carcinoma was given 60 mg kg-1 ALA orally. Serial biopsies of normal and tumour areas were taken over the subsequent 24 h. Fluorescence microscopy of these specimens showed maximum accumulation of PpIX 4 to 6 h after administration of 30 mg kg-1 ALA. There was greater PpIX accumulation in tumour than adjacent normal mucosa in two patients. Preferential PpIX accumulation in tumour was greater in the patient receiving 60 mg kg-1 ALA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318419      PMCID: PMC1968297          DOI: 10.1038/bjc.1993.284

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  A COMPARATIVE STUDY OF PORPHYRIN BIOSYNTHESIS IN DIFFERENT TISSUES.

Authors:  V M SARDESAI; J WALDMAN; J M ORTEN
Journal:  Blood       Date:  1964-08       Impact factor: 22.113

2.  Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms.

Authors:  P Mustajoki; K Timonen; A Gorchein; A M Seppäläinen; E Matikainen; R Tenhunen
Journal:  Eur J Clin Invest       Date:  1992-06       Impact factor: 4.686

3.  Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats.

Authors:  R Van Hillegersberg; J W Van den Berg; W J Kort; O T Terpstra; J H Wilson
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

4.  Neuropharmacology of delta-aminolaevulinic acid--I. Effect of acute administration in rodents.

Authors:  S R Edwards; B C Shanley; J A Reynoldson
Journal:  Neuropharmacology       Date:  1984-04       Impact factor: 5.250

5.  The metabolism of delta -aminolaevulic acid. 1. Normal pathways, studied with the aid of 15N.

Authors:  N I BERLIN; A NEUBERGER; J J SCOTT
Journal:  Biochem J       Date:  1956-09       Impact factor: 3.857

6.  Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor.

Authors:  K R Weishaupt; C J Gomer; T J Dougherty
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

7.  Hematoporphyrin derivative: quantitative uptake in dimethylhydrazine-induced murine colorectal carcinoma.

Authors:  M V Agrez; R E Wharen; R E Anderson; E R Laws; D M Ilstrup; D A Cortese; R G Shorter; M M Lieber
Journal:  J Surg Oncol       Date:  1983-11       Impact factor: 3.454

8.  Porphyrin metabolism in some malignant diseases.

Authors:  M M el-Sharabasy; A M el-Waseef; M M Hafez; S A Salim
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

9.  Fluorescence distribution and photodynamic effect of ALA-induced PP IX in the DMH rat colonic tumour model.

Authors:  J Bedwell; A J MacRobert; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

10.  Photodynamic therapy of the normal rat stomach: a comparative study between di-sulphonated aluminium phthalocyanine and 5-aminolaevulinic acid.

Authors:  C S Loh; J Bedwell; A J MacRobert; N Krasner; D Phillips; S G Bown
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

View more
  40 in total

1.  Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells.

Authors:  R Bachor; E Reich; A Rück; R Hautmann
Journal:  Urol Res       Date:  1996

Review 2.  Photodynamic therapy: a review.

Authors:  J S McCaughan
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

3.  Photodynamic ablation of early cancers of the stomach by means of mTHPC and laser irradiation: preliminary clinical experience.

Authors:  C Ell; L Gossner; A May; H T Schneider; E G Hahn; M Stolte; R Sroka
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

Review 4.  Current concepts in gastrointestinal photodynamic therapy.

Authors:  J Webber; M Herman; D Kessel; D Fromm
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

5.  Clinical spectral characterisation of colonic mucosal lesions using autofluorescence and delta aminolevulinic acid sensitisation.

Authors:  C Eker; S Montán; E Jaramillo; K Koizumi; C Rubio; S Andersson-Engels; K Svanberg; S Svanberg; P Slezak
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

6.  Photodynamic therapy of experimental colonic tumours with 5-aminolevulinic-acid-induced endogenous porphyrins.

Authors:  K Orth; K König; F Genze; A Rück
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

7.  Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestine.

Authors:  Catriona M H Anderson; Mark Jevons; Muthusamy Thangaraju; Noel Edwards; Nichola J Conlon; Steven Woods; Vadivel Ganapathy; David T Thwaites
Journal:  J Pharmacol Exp Ther       Date:  2009-09-29       Impact factor: 4.030

8.  Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX--a pilot study.

Authors:  J Regula; A J MacRobert; A Gorchein; G A Buonaccorsi; S M Thorpe; G M Spencer; A R Hatfield; S G Bown
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

9.  Sufficient PpIX production for PDT even with short contact time of topically applied 5-ALA in rabbit tongues.

Authors:  Takehiro Oura; Hideo Tanaka; Yuji Morimoto; Kazuma Masumoto; Eiji Kohno; Toru Hirano; Fuminori Katou; Kenji Hashimoto
Journal:  Lasers Med Sci       Date:  2007-09-21       Impact factor: 3.161

10.  The proton-coupled oligopeptide transporter 1 plays a major role in the intestinal permeability and absorption of 5-aminolevulinic acid.

Authors:  Yehua Xie; Yongjun Hu; David E Smith
Journal:  Br J Pharmacol       Date:  2015-11-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.